Verona Pharma plc
("Verona Pharma" or the "Company")
Data demonstrating
PDE3/4 inhibitor RPL554 enhances CTFR-dependent currents in cystic
fibrosis airway epithelia
Poster
presented at North American Cystic Fibrosis Conference,
USA
8 October 2015, Cardiff – Verona Pharma plc (AIM: VRP.L),
the drug development company focused on first-in-class medicines to
treat respiratory diseases, announces that a poster will be
presented later today at the North American Cystic Fibrosis
Conference in Phoenix, Arizona,
USA, 8-10 October 2015.
Poster number 231, entitled: “The Dual Phosphodiesterase 3 and 4
Inhibitor, RPL554, Enhances Forskolin-Stimulated, CTFR-Dependent
Currents in Cystic Fibrosis Airway Epithelia” investigated the
effect of RPL554, an inhaled dual PDE3/4 inhibitor, on the Cystic
Fibrosis Transmembrane conductance Regulator (CFTR), an anion
channel that is mutated in Cystic Fibrosis (CF).
In a preclinical model, RPL554 was shown to have
CFTR-stimulatory properties and that CFTR activation by RPL554 is
mediated by its inhibition of PDE4 in cells from CF patients with
the R117H/F508del mutation. The data reported suggest that CFTR
activation may contribute to the action of inhaled RPL554 in
chronic obstructive pulmonary disease (COPD) and asthma, and
further support the concept that RPL554 may be an attractive novel
therapeutic option for the treatment of CF, an orphan disease with
about 70,000 people afflicted worldwide. This work was partly
funded through the Venture and Innovation Award which Verona Pharma
received from the UK CF Trust in November
2014. This poster also extends the work presented at the
2014 North American Cystic Fibrosis Conference in Atlanta, Georgia, USA, announced in a press
release on 29 September 2014.
Verona Pharma's lead drug, RPL554, is a first-in-class drug
currently in Phase II trials as a nebulised treatment for acute
exacerbations of COPD in the hospital setting.
The full abstract for this poster is reproduced below.
THE DUAL PHOSPHODIESTERASE 3 AND 4 INHIBITOR, RPL554 ENHANCES
FORSKOLIN-STIMULATED, CFTR-DEPENDENT CURRENTS IN CYSTIC FIBROSIS
AIRWAY EPITHELIA
Mark J. Turner1,
Elizabeth Matthes1,
Kathy Abbott-Banner2,
Scott H. Randell3 and
John W. Hanrahan1
1 Dept. of Physiology, McGill
University, Montréal, Canada
2 Verona Pharma plc, London
UK
3 UNC Chapel Hill,
Chapel Hill NC
Efficient spatial and temporal regulation of cAMP is required
for cell signal transduction by protein kinase A (PKA) and the
exchange protein directly activated by cyclic AMP (EPAC). The
enzymes responsible for degrading cAMP are the cyclic nucleotide
phosphodiesterases (PDEs), of which at least 11 different isoforms
have been identified in humans. The Cystic Fibrosis Transmembrane
conductance Regulator (CFTR) is the PKA-activated anion channel
that is mutated in Cystic Fibrosis (CF). Inhibitors of both PDE3
and PDE4 have been shown to elevate intracellular cAMP and activate
CFTR in various airway epithelial models, suggesting they could
serve as potential therapeutic targets for CF. Using qPCR, of the 7
PDEs surveyed, we found PDE4D to be the most highly expressed
isoform in CFBE-WT and CFBE-F508del cells, contributing ~64% of the
total PDE expression in both cell lines (n=3). Relatively high
levels of PDE7A (11.1 ± 2.6% of the total in WT cells and 7.5 ±
0.7% in ?F-508 cells; n=4; p>0.05) and PDE8A (27.2 ± 4.7% in WT
cells and 18.1 ± 1.2% in F508del cells; n=3; p<0.01) were also
observed, suggesting they may also contribute to CFTR regulation.
RPL554, a dual PDE3/4 inhibitor in Ph2a clinical trials, is a
"first-in-class" inhaled treatment for respiratory diseases and has
been shown to have significant bronchodilator and anti-inflammatory
(including anti-neutrophilic) activity in humans (Franciosi, L.G.,
et al., Lancet Respir Med, 2013. 1(9) 714-727). RPL554
caused a dose-dependent increase in CFTR-dependent short circuit
current (Isc) across CFBE-WT cells, with 10?M RPL554 eliciting 65.9
± 4.5% (n=3) of the maximal forskolin response. Similar results
were also obtained with primary WT human bronchial epithelial
cells. To determine if the RPL554 stimulation was mediated by
inhibition of PDE3 or PDE4 in primary human bronchial epithelial
cells (HBEs), and whether PDE inhibition was able to activate CFTR
in CF airway epithelia, the specific PDE inhibitors Milrinone
(PDE3) and Rolipram (PDE4) were tested on HBEs from three
R117H/F508del CF patients. Forskolin (2?M) increased Isc by 1.43 ±
0.11?A cm-2 (n=16), which was enhanced to 2.06 ± 0.19?A cm-2 in
cells that had been pre-treated with Lumacaftor for 24 h
(p<0.01; n=15) demonstrating Lumacaftor was able to act as a
corrector in these cells. The acute addition of Rolipram, RPL554,
and Rolipram + Milrinone (without Lumacaftor pre-treatment)
increased forskolin-stimulated Isc by 0.92 ± 0.17?A cm-2
(p<0.01; n=5), 0.92 ± 0.19?A cm-2 (p<0.05; n=8) and 0.64 ±
0.14?A cm-2 (p<0.05; n=9), respectively. No increase was induced
by Milrinone alone (Isc increased by -0.03 ± 0.10?A cm-2; n=5). The
similar magnitude of the response caused by Rolipram and RPL554,
together with the absence of an effect of Milrinone, suggests that
the CFTR activation by RPL554 is mediated by inhibition of PDE4.
These data suggest that CFTR activation may contribute to the
action of inhaled RPL554 in COPD and asthma and further support the
concept that RPL554 may be an attractive novel therapeutic option
for the treatment of CF.
Work supported by a Venture and Innovation Award from the UK CF
Trust.
-Ends-
For further information please
contact:
Verona Pharma plc |
Tel: +44 (0)20 3283 4200 |
Jan-Anders Karlsson, Chief Executive
Officer |
|
|
|
N+1 Singer |
Tel: +44 (0)20 7496 3000 |
Aubrey Powell / Jen Boorer |
|
|
|
FTI Consulting |
Tel: +44 (0)20 3727 1000 |
Simon Conway /
Stephanie Cuthbert /
Natalie Garland-Collins |
|
Notes to Editors
About Verona Pharma plc
Verona Pharma plc is a UK-based clinical stage biopharmaceutical
company focused on the development of innovative prescription
medicines to treat respiratory diseases with significant unmet
medical needs, such as chronic obstructive pulmonary disease
(COPD), asthma and cystic fibrosis.
Verona Pharma's lead drug, RPL554, is a first-in-class drug
currently in Phase II trials as a nebulised treatment for acute
exacerbations of COPD in the hospital setting. The drug is a
dual phosphodiesterase (PDE) 3/4 inhibitor and therefore has both
bronchodilator and anti-inflammatory effects, which are essential
to the improvement of patients with COPD and asthma.
Verona Pharma is also building a broader portfolio of
RPL554-containing products to maximise its benefit to patients and
its value. This includes the very significant markets for
COPD and asthma maintenance therapy. The Company is also
exploring the potential of the drug in different diseases, such as
cystic fibrosis, where it is in pre-clinical testing and has
received a Venture and Innovation Award from the Cystic Fibrosis
Trust.